Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Tempo Pharmaceuticals Closes $12.1 Million in Series A Funding

Abstract:
Tempo Pharmaceuticals, a biopharmaceutical company focused on novel, intelligently designed nanoparticle-based drugs, today announced that it has closed a $12.1 million Series A financing. Proceeds from the financing will be used to accelerate the development of Tempo's preclinical pipeline of multi-compartmental, nanoparticle-based drugs that have the potential to substantially improve the efficacy and safety of existing and new therapeutics.

Tempo Pharmaceuticals Closes $12.1 Million in Series A Funding

Tempo Pharmaceuticals | Posted on May 23rd, 2007

Venrock of New York, N.Y. and Polaris Venture Partners of Waltham, MA co-led the round with participation from Lux Capital of New York, N.Y. and William H. Rastetter, Ph.D., former executive chairman of Biogen Idec and a partner at Venrock. Tempo was previously co-founded and seed funded by Polaris.

"Attracting additional capital from outstanding investors is a testament to the opportunity that we have to build a leadership position in the emerging field of nanopharmaceuticals, which has the potential to revolutionize drug therapy over the next five to ten years," said Alan Crane, CEO of Tempo Pharmaceuticals and a venture partner at Polaris. "This funding allows the advancement of our preclinical pipeline towards human clinical trials and will support the generation of data to enable strategic partnerships with leading biotechnology and pharmaceutical companies."

Based on technology exclusively licensed from the Massachusetts Institute of Technology, Tempo is focused on significantly improving the efficacy and safety profile of existing and new drugs employing advances in nanotechnology. The Company utilizes its proprietary Nanocell™ technology to develop multi-compartmental, nanoparticle-based therapeutics in which two drugs with varied release rates are packaged within a single nanoparticle. This approach allows for sequential delivery of drugs, optimizing the location, rate of release and synergistic effect of the two therapies while minimizing toxicities.

The potential of the Nanocell™ technology was highlighted by preclinical data published in the July 28, 2005 edition of the journal Nature in a publication entitled "Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system." In the study, researchers designed a Nanocell™ that preferentially distributes to the tumor; it then sequentially releases a vascular targeting drug, leading to the collapse of the vascular network and imprisoning the nanoparticle within the tumor, followed by the subsequent release of a potent anti-tumor drug.

The data in the Nature article demonstrates that by trapping the drugs in the tumor and sequentially releasing them, the Nanocell™ dramatically extends survival time and inhibits tumor growth in mice compared to positive controls. In addition, the data shows that the Nanocell™ provides a significant safety advantage in the animal models studied compared with positive controls.

Using its proprietary Nanocell™ technology, Tempo is developing a deep pipeline of preclinical candidates. Its current focus is on application of the technology to both existing and novel drugs for oncology, autoimmune and inflammatory diseases.

"Venrock seeks to invest in biopharmaceutical companies pursuing disruptive approaches with the potential to dramatically improve the way diseases are treated. Tempo is being built on truly important new science aimed at bringing nanotechnology and combinatorial therapeutics to bear on the treatment of major diseases," said Bryan Roberts, Ph.D., managing general partner at Venrock.

"Combining world-class science with the reduced regulatory risk of utilizing existing drugs and the opportunity to create both partnering opportunities and a deep proprietary pipeline, Tempo has constructed an exciting portfolio of opportunities. We are delighted to be able to work with such an experienced and proven management team and an outstanding group of investors," said Terry McGuire, managing general partner at Polaris Venture Partners.

####

About CAMBRIDGE, MA
Tempo Pharmaceuticals is a private biopharmaceutical company focused on the development of novel, nanotechnology-based therapeutics in the areas of oncology, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Millennium Pharmaceuticals, Pfizer, Pharmacia, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center. Tempo is located in Cambridge, Massachusetts.

For more information, please click here

Contacts:
Yates & Associates
Adriana Jenkins
617-744-1713

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Nanometrics Announces Upcoming Investor Events November 19th, 2014

Eight19 secures £1m funding: Investment to develop production technology, and expand commercial activities for organic photovoltaics November 19th, 2014

Arrowhead to Present at Upcoming Conferences November 15th, 2014

Harris & Harris Group Reports Financial Statements as of September 30, 2014 November 11th, 2014

Nanomedicine

Silver Nanoparticles Produced in Iran from Forest Plants Extract November 20th, 2014

Tokyo Institute of Technology research: Protein-engineered cages aid studies of cell functions November 19th, 2014

A novel method for identifying the body’s ‘noisiest’ networks November 19th, 2014

Arrowhead Files for Regulatory Permission to Begin Phase 1 Trial of RNAi Therapeutic ARC-AAT November 18th, 2014

Announcements

Purdue 3-D printing innovation capable of making stronger, lighter metal works for auto, aerospace industries November 20th, 2014

Leica Microsystems Presents Universal Hybrid Detector for Single Molecule Detection and Imaging at SfN and ASCB: Leica HyD SMD - the Optimal Detector for Precise and Reliable SMD data November 20th, 2014

Silver Nanoparticles Produced in Iran from Forest Plants Extract November 20th, 2014

Nano Sorbents Able to Remove Pollutions Caused by Oil Derivatives November 20th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE